Core Viewpoint - The company, Bluestar Medical (002382.SZ), announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for the Lithonic™ coronary intravascular shockwave treatment system, which is designed to treat severely calcified narrow areas in blood vessels [1] Group 1 - The Lithonic™ system is intended for use in areas where balloon dilation is insufficient or stents cannot be evenly expanded due to calcification [1] - The system operates on the principle of utilizing electrodes in an electrolyte solution to generate high-pressure shockwaves, which are precisely delivered within the blood vessels to modify calcified lesions [1] - This innovative approach aims to reduce the risk of complications associated with traditional treatments for calcified lesions, such as vascular perforation and no-reflow phenomena [1]
蓝帆医疗(002382.SZ):Lithonic冠脉血管内冲击波治疗系统获CE认证